*Potential sales of $35 bln a year over next 10 years- Citigroup. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.» Read More
*Potential sales of $35 bln a year over next 10 years- Citigroup. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.
In a story May 20 about Pfizer Inc. halting a cancer drug study, The Associated Press erroneously reported the uses of two of the drugmaker's existing cancer medicines. Bosulif is approved for use in certain patients with chronic myelogenous leukemia and Inlyta is for advanced kidney cancer.
WESTON, Mass.-- Specialty drugmaker Biogen Idec said Tuesday it submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The company also plans to submit the drug to the European Medicines Agency in coming weeks. Shares of Biogen Idec Inc. rose $6.15, or 2.7 percent, to close Tuesday at $231.33.
REDWOOD CITY, Calif.-- Shares of AcelRx Pharmaceuticals Inc. hit an all-time high price Tuesday, after the specialty drugmaker said its NanoTab pain treatment system met its main goal in late-stage research, and the company is preparing to submit it to regulators for approval.
The revenue hit faced by Cubist Pharmaceuticals from generic competition may not be as dramatic as it has been for other drugs, Cantor Fitzgerald said Tuesday, as it raised its rating on the drugmaker.
SAN FRANCISCO, May 21- Amazon.com Inc has been given a security clearance by the U.S. government that will make it easier for federal agencies to use its cloud computing services. The accreditation covers all AWS data centers in the United States, the company said on Tuesday.
Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drug wasn't helping patients live longer.
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
The LA Times is reporting former Navy Secretary Richard J. Danzig urged the government to counter what he called a major threat to national security, with CNBC's Hampton Pearson.
May 20- Merck& Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company's proposed dosing levels.
May 20- Generic drugmaker Actavis Inc, which has been the subject of intense takeover speculation, said on Monday that it had struck a deal to buy specialty pharmaceuticals company Warner Chilcott Plc for $8.5 billion in stock.
Cramer has been looking at long-term losers to see if any show potential. He’s found something.
Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.
SANTA CLARA, Calif.-- Drug developer XenoPort said Friday that its treatment for restless leg syndrome, Horizant, will likely be available to U.S. patients in early June. Last month XenoPort Inc. said that there was a shortage of Horizant, with patients telling them that they were unable to fill prescriptions.
*Novartis' one-third stake in Roche built up under Vasella. ZURICH, May 16- A changing of the guard at Switzerland's two biggest drugmakers is fuelling talk that Novartis may finally sell its multi-billion-dollar stake in cross-town rival Roche, potentially unlocking value for both sets of shareholders.
NEW YORK-- Shares of Oncothyreon Inc. fell Thursday after the drug developer announced new clinical trial data about an experimental lung cancer treatment that failed to improve overall survival rate. THE SPARK: Oncothyreon said that it identified some patients who appeared to live longer after treatment with Stimuvax.
The Parsippany, N.J., company's stock had already climbed about 16 percent since last Friday, when Actavis and Irish drugmaker Warner Chilcott PLC said that they were in early talks about a possible combination but had reached no agreement yet. Actavis shares rose 62 cents to $124.50 in premarket trading about 40 minutes ahead of Thursday's market opening.
NEW YORK, May 15- Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
CHICAGO/ NEW YORK, May 15- Shares of drugmaker Bristol-Myers Squibb Co rose to a 10- year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.
CHICAGO/ NEW YORK, May 15- Shares of drugmaker Bristol-Myers Squibb Co rose to a ten-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy betting in the options market suggesting investors see more gains in the stock.